Key result
Estradiol administration improved flow-mediated dilatation more in women within 5 years of menopause than in those beyond 5 years.
Why the study?
Does acute and chronic estradiol administration improve flow-mediated dilatation differently based on time since menopause in postmenopausal women?
Does acute and chronic estradiol administration improve flow-mediated dilatation differently based on time since menopause in postmenopausal women?
The beneficial effects of estradiol on endothelial function in postmenopausal women are attenuated with increasing time since menopause, supporting the timing hypothesis for hormone therapy.
Answers are grounded in this paper and cite their sources.
Supports timing hypothesis for estradiol effects; hypothesis-generating and should not yet change clinical practice.
OBJECTIVE: We evaluated whether time since menopause influences the acute and chronic effect of Estradiol (E) on vascular endothelial function. METHODS AND RESULTS: We studied flow-mediated dilatation (FMD) in 134 postmenopausal women (PMW) before and after acute and chronic E administration. At baseline FMD was inversely associated to time from menopause (r=-0.67, P<0.001) and age (r=-0.43, P<0.05), in exogenous estrogen naïve but not in previous users. Acute and chronic E improved endothelial function in all women. E administration improved FMD more in women within 5 years since menopause than in those with more than 5 years since menopause (76% and 74% versus 45% and 48%, acute and chronic E, respectively; P<0.05). Among women with more than 5 years since menopause acute and chronic E increased FMD more in previous E users than in nonusers (59% and 63% versus 31% and 38%, acute and chronic E, respectively; P<0.01). Multivariate analysis showed that time from menopause was a predictor of impaired FMD and of its improvement after acute and chronic E. CONCLUSIONS: Time from menopause influences FMD in PMW. The acute and chronic effect of E on FMD is time dependent and is reduced by a longer time since menopause.
No takes yet. Share an insight, caveat, or question.
Vitale et al. (2007) studied Postmenopause (n=134). Estradiol vs. Women >5 years since menopause was evaluated on Improvement in flow-mediated dilatation (FMD) (p=<0.05). Estradiol administration improved flow-mediated dilatation more in women within 5 years of menopause than in those beyond 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: